Last reviewed · How we verify
NCT07171723: SILENCED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment
Phase 1, PHASE2 trial testing Liver-Expressed Antimicrobial Peptide 2 (LEAP2) in Obesity &Amp; Overweight in 24 participants. Currently enrolling.
14 December 2025
Quick facts
| Lead sponsor | University Hospital, Gentofte, Copenhagen |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 1 September 2025 |
| Primary completion | 14 December 2025 |
| Estimated completion | 1 February 2026 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Liver-Expressed Antimicrobial Peptide 2 (LEAP2) — full drug profile →
- Placebo (saline)
Conditions studied
- Obesity &Amp; Overweight — all drugs for Obesity &Amp; Overweight →
Sponsor
University Hospital, Gentofte, Copenhagen
Who can join
Adults 18 to 65, any sex, with Obesity &Amp; Overweight. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical study investigates how blocking the hunger-related ghrelin receptor affects appetite and metabolism in individuals with obesity who are treated with semaglutide (a GLP-1 receptor agonist). LEAP2, a naturally occurring hormone that inhibits the ghrelin receptor, is used as the investigational compound. The objective of the study is to clarify how the ghrelin system functions when appetite is suppressed by semaglutide treatment. Participants will receive either LEAP2 or placebo during two experimental visits in a randomized, double-blind, crossover design. The investigators will assess food intake, appetite sensations, glucose metabolism, and hormonal responses. By examining the interaction between semaglutide and ghrelin signaling, the study aims to improve understanding of how multiple appetite-regulating systems interact and whether additional hunger signals remain active during GLP-1 treatment. The findings may inform the development of future treatments for individuals with obesity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07171723
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity &Amp; Overweight
Currently open trials in the same condition.
- NCT07231484 — Effects of Grape Consumption on the Immune-Gut Axis in Obesity · NA · recruiting
- NCT07218588 — Sanctuary Farm Prescription in Adolescents · NA · recruiting
- NCT07245771 — Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of R · Phase 1, PHASE2 · recruiting
- NCT07240246 — Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults · NA · active not recruiting
- NCT07114289 — Spontaneous Breathing Trials Using Pressure Support or T-Piece in Overweight and Obese Patients · NA · recruiting
Other University Hospital, Gentofte, Copenhagen trials
Trials by the same sponsor.
- NCT06934473 — Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals · NA · recruiting
- NCT06845033 — Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity · NA · not yet recruiting
- NCT06787001 — Understanding How Gut and Brain Barriers Are Linked to Inflammation in Obesity · completed
- NCT06881459 — The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 Diabetes · NA · completed
- NCT06895408 — Separate and Combined Extrapancreatic Effects of GIP and GLP-1 · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07171723 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Gentofte, Copenhagen
- Last refreshed: 18 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07171723.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing